NCT00698945已完成4 期
Randomized, Investigator Masked Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Trough and peak intraocular pressure
研究概览
简要总结
To assess the additional benefit of common adjunctive classes on the diurnal IOP curve in patients assessed as needing additional treatment to reach target intraocular pressure (IOP). To demonstrate superiority of IOP control with Istalol 0.5% QD compared to Brimonidine Tartrate 0.2% BID as adjunctive therapy in adults with uncontrolled IOP's (determined by P.I. based on target pressures) currently treated with Latanoprost 0.05% in the study eye(s).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients, male or female of any race or ethnicity, 18 years of age or older, diagnosed with ocular hypertension or open-angle glaucoma (with or without pseudoexfoliative or pigmentary dispersion component).
- •Stable use of Latanoprost 0.005% for a minimum of 30 days prior to screening visit.
- •VA of 20/200 or better in either eye
- •Pachymetry of 600 microns or less
- •Visual Field within 6 months of screening visit
- •Patients who use contact lenses are allowed to participate provided that they will remove lenses 15 minutes before dosing
- •Patients who satisfy all informed consent requirements may be included in the study.
排除标准
- •Females of childbearing potential (those who are not surgically sterile, postmenopausal or using a reliable birth control method) will be excluded from the study.
- •Any allergic component or contraindication to the study medications
- •Pachymetry of 600 microns or greater
- •Systemic corticosteroids not on a stable regimen within 30 days of screening visit.
- •Any concurrent topical agents that can not be discontinued during the course of the trial (natural tears are acceptable)
- •Significant ocular surface abnormalities
- •Patients with any form of glaucoma other than ocular hypertension or open-angle glaucoma
- •Patients who have been on an investigational therapy within 30 days prior to screening visit
- •History of ocular trauma within the past 3 months
- •Intraocular surgery within the past 3 months
- •Ocular laser surgery within the past 3 months
- •Any abnormality preventing reliable applanation tonometry of either eye
- •VA of 20/200 or greater in either eye
- •History or evidence of clinically significant illness or conditions which would make the patient, in the opinion of the investigator, not suitable for the study
研究组 & 干预措施
2
Active Comparator
Alphagan
干预措施: Alphagan (Drug)
1
Active Comparator
Istalol and Optive
干预措施: Istalol and Optive (Drug)
结局指标
主要结局
Trough and peak intraocular pressure
时间窗: 2-4 months
次要结局
- Tolerability of study medication(2-4 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Effect of Laser Photobiomodulation in Improving Mouth Opening in Oral Submucous FibrosisOral Submucous FibrosisNCT06639009Dr. Shalini Gupta315
已完成
3 期
SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV InfectionHIV InfectionsNCT00323544Gilead Sciences220
已完成
不适用
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular HypertensionGlaucoma, Open-AngleOcular HypertensionNCT01646151Allergan2,580
终止
3 期
Dynepo Infrequent Dosing StudyKidney FailureAnemiaNCT00450333Shire407
已完成
不适用
Effect of Bispectral Index Monitoring (BIS) on Body Movement of Outpatients Undergoing GastroscopyGastroscopyNCT05773807West China Hospital400